

PURPOSE OF BILL: HB 1316

To require coverage for lung cancer screenings.

ACTUARIAL STATEMENT

The Fiscal Impact Statement was prepared according to generally accepted actuarial principles and practices, in compliance with ACT 112. The Statement provides an estimate of the financial and actuarial effect of the proposed change(s) on the Plans, if possible. The Statement makes no comment or opinion with regard to the merits of the measure for which the Statement is prepared; however, any identified technical or mechanical defects have been noted.

We have reviewed the input and results of our analysis for reasonableness and relied upon the data and information provided by the Plans and their Claims Processing Contractors.

A handwritten signature in black ink, appearing to read "Patrick Klein".

3/14/2025

Patrick Klein, FSA, MAAA
Vice President, Segal

Date

A handwritten signature in black ink, appearing to read "Matthew Kersting".

3/14/2025

Matthew Kersting, FSA, MAAA
Vice President, Segal

Date

PROJECTED COSTS

Plan	Plan Design Change	Estimated Cost/(Savings)
EBD	No Change	No Impact

PRICING APPROACH AND COMMENTS

House Bill 1316 requires coverage for lung cancer screenings and follow-up healthcare services according to American Cancer Society guidelines. Through the Affordable Care Act (ACA), lung cancer screenings for adults aged 50 to 80 at high risk for lung cancer due to heavy smoking or have quit in the past 15 years are mandated as preventive care benefits not subject to deductible, copayment, or coinsurance. The ACA lung cancer screenings align with the American Cancer Society guidelines. The coverage for lung cancer screening required by House Bill 1316 was confirmed as already covered by EBD. Therefore, this bill has no fiscal impact on EBD.